Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
D-Sight S.L. logo — Spin-off company from VHIR developing new innovative treatme...

D-Sight S.L.

Spin-off company from VHIR developing new innovative treatments for neurodegenerative diseases of the retina.

Founded 2023 Spain Spain 2 employees Seed Total: $1.00M Biotechnology, Health Care

General Information

Company Name D-Sight S.L.
Founded Year 2023
Location Spain Spain
Employees 2
Industries Biotechnology, Health Care
Funding Stage Seed
Business Model B2B, D2C
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with D-Sight S.L.. To contact D-Sight S.L., visit dsight.es.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does D-Sight S.L. compare?

A PDF of D-Sight S.L. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting D-Sight S.L. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About D-Sight S.L.

D-Sight S.L., a promising biotech venture, is a spin-off company from the Vall d’Hebron Institute of Research (VHIR) established in 2023. Focused on the biotechnology and healthcare sectors, D-Sight seeks to innovate treatments for neurodegenerative retina diseases.

At the forefront of their development is a potentially transformative first-in-class eye drop aimed at preventing and treating diabetic retinopathy during its initial stages. This innovation highlights D-Sight’s commitment to reshaping how retinal diseases are treated.

Headquartered in Spain, D-Sight attracted significant attention from investors, securing a €1.00M seed round investment from Clave Capital in May 2023. Led by an experienced team with a strong connection to VHIR, the company's strategic focus on unmet needs in retina healthcare positions it as a compelling opportunity for investment in the biotech field.

Business keywords: neurodegenerative diseases, retina health, diabetic retinopathy, preventable blindness, innovative treatments, eye drop formulation, early-stage intervention, pharmaceutical development, retinal diseases, biopharmaceuticals, vision care, spin-off company, medical research

Services & Products

Development of neuroprotective eye drops
Research and clinical translation for retinal diseases
Non-invasive early-stage intervention solutions

Target Customers

Individuals with diabetic retinopathy Individuals with glaucoma Patients at risk of vision loss

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round D €1.00M 1
Clave Capital
Clave Capital
03 May 2023

D-Sight S.L. Alternatives & Competitors

View All Alternatives
D-Sight S.L. vs
Inotek Pharmaceuticals
Inotek Pharmaceuticals

Innovative molecules addressing critical eye diseases for millions.

Venture round
Biotechnology, Health Care
D-Sight S.L. vs
Inflammx Therapeutics, Inc.
Inflammx Therapeutics, Inc. United States

Modulation of Inflammasome mediated Autoinflammation - in Ophthalmology, Nephropathy and Neurodegen...

Venture round
3 employees
Biotechnology, Health Care
D-Sight S.L. vs
Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. United States

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experienc...

Post-IPO Equity
325 employees
Biotechnology, Health Care
View all alternatives

FAQ About D-Sight S.L.

Spin-off company from VHIR developing new innovative treatments for neurodegenerative diseases of the retina.
D-Sight S.L. was founded in 2023.
D-Sight S.L. is headquartered in Spain.
D-Sight S.L. operates in Biotechnology and Health Care. Its work centres on neurodegenerative diseases, retina health, diabetic retinopathy and preventable blindness. Its customers include Individuals with diabetic retinopathy, Individuals with glaucoma and Patients at risk of vision loss.
D-Sight S.L. has a B2B and D2C business model. Its revenue comes from Product Sales, Licensing and Service Fee.
D-Sight S.L. has approximately 2 employees.
D-Sight S.L. has completed 1 funding round, raising a total of $1.00M. The latest funding stage is Seed.
D-Sight S.L. offers: Development of neuroprotective eye drops, Research and clinical translation for retinal diseases, Non-invasive early-stage intervention solutions.
Top alternatives and competitors to D-Sight S.L. include Inotek Pharmaceuticals, Inflammx Therapeutics, Inc., Ocular Therapeutix, Inc., Epion Therapeutics, iCare. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
D-Sight S.L. and Inotek Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for D-Sight S.L., https://bouncewatch.com/company/d-sight-sl, updated 16 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes